These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 19157637)
21. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro. Ferrari F; Bellone S; Black J; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Menderes G; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD J Exp Clin Cancer Res; 2015 Oct; 34():123. PubMed ID: 26474755 [TBL] [Abstract][Full Text] [Related]
22. Opsonization with a trifunctional bispecific (alphaCD3 x alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes. Schmitt M; Schmitt A; Reinhardt P; Thess B; Manfras B; Lindhofer H; Riechelmann H; Wiesneth M; Gronau S Int J Oncol; 2004 Oct; 25(4):841-8. PubMed ID: 15375531 [TBL] [Abstract][Full Text] [Related]
23. Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells. Herrmann I; Baeuerle PA; Friedrich M; Murr A; Filusch S; Rüttinger D; Majdoub MW; Sharma S; Kufer P; Raum T; Münz M PLoS One; 2010 Oct; 5(10):e13474. PubMed ID: 20976159 [TBL] [Abstract][Full Text] [Related]
24. Caspase-independent cell death induced by anti-CD2 or staurosporine in activated human peripheral T lymphocytes. Déas O; Dumont C; MacFarlane M; Rouleau M; Hebib C; Harper F; Hirsch F; Charpentier B; Cohen GM; Senik A J Immunol; 1998 Oct; 161(7):3375-83. PubMed ID: 9759854 [TBL] [Abstract][Full Text] [Related]
25. Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. d'Argouges S; Wissing S; Brandl C; Prang N; Lutterbuese R; Kozhich A; Suzich J; Locher M; Kiener P; Kufer P; Hofmeister R; Baeuerle PA; Bargou RC Leuk Res; 2009 Mar; 33(3):465-73. PubMed ID: 18835037 [TBL] [Abstract][Full Text] [Related]
26. Target-dependent T-cell activation by coligation with a PSMA x CD3 diabody induces lysis of prostate cancer cells. Bühler P; Molnar E; Dopfer EP; Wolf P; Gierschner D; Wetterauer U; Schamel WW; Elsässer-Beile U J Immunother; 2009; 32(6):565-73. PubMed ID: 19483653 [TBL] [Abstract][Full Text] [Related]
27. Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cells. Torisu-Itakura H; Schoellhammer HF; Sim MS; Irie RF; Hausmann S; Raum T; Baeuerle PA; Morton DL J Immunother; 2011 Oct; 34(8):597-605. PubMed ID: 21904216 [TBL] [Abstract][Full Text] [Related]
28. Minimal costimulatory requirements for T cell priming and TH1 differentiation: activation of naive human T lymphocytes by tumor cells armed with bifunctional antibody constructs. Kufer P; Zettl F; Borschert K; Lutterbüse R; Kischel R; Riethmüller G Cancer Immun; 2001 Nov; 1():10. PubMed ID: 12747771 [TBL] [Abstract][Full Text] [Related]
30. [T-cells activated with a trifunctional bi-specific antibody in head and neck cancer]. Gronau S; Schmitt M; Reinhardt P; Wiesneth M; Riechelmann H Laryngorhinootologie; 2005 Nov; 84(11):822-8. PubMed ID: 16358189 [TBL] [Abstract][Full Text] [Related]
31. Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen. Bluemel C; Hausmann S; Fluhr P; Sriskandarajah M; Stallcup WB; Baeuerle PA; Kufer P Cancer Immunol Immunother; 2010 Aug; 59(8):1197-209. PubMed ID: 20309546 [TBL] [Abstract][Full Text] [Related]
32. An epithelial cell adhesion molecule- and CD3-bispecific antibody plus activated T-cells can eradicate chemoresistant cancer stem-like pancreatic carcinoma cells in vitro. Umebayashi M; Kiyota A; Koya N; Tanaka H; Onishi H; Katano M; Morisaki T Anticancer Res; 2014 Aug; 34(8):4509-19. PubMed ID: 25075094 [TBL] [Abstract][Full Text] [Related]
33. Mechanisms of cytotoxicity used by human peripheral blood CD4+ and CD8+ T cell subsets. The role of granule exocytosis. Smyth MJ; Ortaldo JR J Immunol; 1993 Jul; 151(2):740-7. PubMed ID: 8101537 [TBL] [Abstract][Full Text] [Related]
34. Assessing main death pathways in T lymphocytes from HIV infected individuals. Massanella M; Curriu M; Carrillo J; Gómez E; Puig J; Navarro J; Dalmau J; Martínez-Picado J; Crespo M; Cabrera C; Negredo E; Clotet B; Blanco J Cytometry A; 2013 Jul; 83(7):648-58. PubMed ID: 23650261 [TBL] [Abstract][Full Text] [Related]
35. Bispecific antibody-mediated cytotoxicity by CD4+ and CD8(+)-activated T cells generated from leukemia patients after allogeneic bone marrow transplantation. Hattori K; Tsukamoto H; Ohta S; Yabe M; Yabe H; Kato S; Takakura I; Ueda R; Habu S; Nishimura T Bone Marrow Transplant; 1995 Feb; 15(2):193-8. PubMed ID: 7773208 [TBL] [Abstract][Full Text] [Related]
36. IL-27 increases the proliferation and effector functions of human naïve CD8+ T lymphocytes and promotes their development into Tc1 cells. Schneider R; Yaneva T; Beauseigle D; El-Khoury L; Arbour N Eur J Immunol; 2011 Jan; 41(1):47-59. PubMed ID: 21182076 [TBL] [Abstract][Full Text] [Related]
37. A photosensitizer delivered by bispecific antibody redirected T lymphocytes enhances cytotoxicity against EpCAM-expressing carcinoma cells upon light irradiation. Blaudszun AR; Moldenhauer G; Schneider M; Philippi A J Control Release; 2015 Jan; 197():58-68. PubMed ID: 25449805 [TBL] [Abstract][Full Text] [Related]
38. Mechanisms of lysis by cytotoxic T lymphocyte clones. Lytic activity and gene expression in cloned antigen-specific CD4+ and CD8+ T lymphocytes. Lancki DW; Hsieh CS; Fitch FW J Immunol; 1991 May; 146(9):3242-9. PubMed ID: 1673149 [TBL] [Abstract][Full Text] [Related]